Skip to main content
Journal cover image

Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network.

Publication ,  Journal Article
Ahmad, J; Li, Y-J; Phillips, E; Dellinger, A; Hayashi, PH; Chalasani, N; Fontana, RJ; Kleiner, DE; Barnhart, HX; Hoofnagle, JH ...
Published in: Liver Int
February 2025

BACKGROUND AND AIMS: Short courses of intravenous (iv) methylprednisolone (MP) can cause drug induced liver injury (DILI). The aim of this study was to assess the clinical features and HLA associations of MP-related DILI enrolled in the US DILI Network (DILIN). METHODS: DILIN cases with MP as a suspected drug were reviewed. DILIN causality scoring was assigned on a 5-point scale (definite, highly likely, probable, possible, unlikely). All cases with MP causality scores of definite, highly likely or probable were analysed. HLA data from direct sequencing were analysed. RESULTS: Eleven cases of definite, highly likely, or probable MP DILI were identified. The median age was 48 years; 73% were female; median latency to onset was 30 days; 55% were jaundiced; and all had hepatocellular injury with one patient requiring transplantation. Nine of the 11 cases were in patients with multiple sclerosis (MS). Liver biopsies in 7 cases revealed mild acute hepatitis with/without cholestasis. HLA data demonstrated that HLA-DRB1*15:01, the primary HLA class II allele associated with MS was over-represented. HLA-DQB1*06:02-HLA-DQA1*01:02 which is haplotypic with the HLA-DRB1*15 haplotype was more common in the MP DILI cases compared to other DILI controls (p = 0.03) and to DILI controls exposed to MP (p = 0.04). CONCLUSION: MP DILI is characterised by hepatocellular injury, short latency and generally rapid recovery. There was no independent HLA haplotype associated with MP DILI.

Duke Scholars

Published In

Liver Int

DOI

EISSN

1478-3231

Publication Date

February 2025

Volume

45

Issue

2

Start / End Page

e16242

Location

United States

Related Subject Headings

  • United States
  • Middle Aged
  • Methylprednisolone
  • Male
  • Liver
  • Humans
  • HLA-DRB1 Chains
  • Gastroenterology & Hepatology
  • Female
  • Chemical and Drug Induced Liver Injury
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahmad, J., Li, Y.-J., Phillips, E., Dellinger, A., Hayashi, P. H., Chalasani, N., … Drug‐Induced Liver Injury Network. (2025). Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network. Liver Int, 45(2), e16242. https://doi.org/10.1111/liv.16242
Ahmad, Jawad, Yi-Ju Li, Elizabeth Phillips, Andrew Dellinger, Paul H. Hayashi, Naga Chalasani, Robert J. Fontana, et al. “Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network.Liver Int 45, no. 2 (February 2025): e16242. https://doi.org/10.1111/liv.16242.
Ahmad J, Li Y-J, Phillips E, Dellinger A, Hayashi PH, Chalasani N, et al. Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network. Liver Int. 2025 Feb;45(2):e16242.
Ahmad, Jawad, et al. “Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network.Liver Int, vol. 45, no. 2, Feb. 2025, p. e16242. Pubmed, doi:10.1111/liv.16242.
Ahmad J, Li Y-J, Phillips E, Dellinger A, Hayashi PH, Chalasani N, Fontana RJ, Kleiner DE, Barnhart HX, Hoofnagle JH, Drug‐Induced Liver Injury Network. Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network. Liver Int. 2025 Feb;45(2):e16242.
Journal cover image

Published In

Liver Int

DOI

EISSN

1478-3231

Publication Date

February 2025

Volume

45

Issue

2

Start / End Page

e16242

Location

United States

Related Subject Headings

  • United States
  • Middle Aged
  • Methylprednisolone
  • Male
  • Liver
  • Humans
  • HLA-DRB1 Chains
  • Gastroenterology & Hepatology
  • Female
  • Chemical and Drug Induced Liver Injury